Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
881 to 900 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience. | Haematologica | 2023 | 36794504 | PubTator, text mining | PubMed |
| Identification of a novel immune-related gene signature for prognosis and the tumor microenvironment in patients with uveal melanoma combining single-cell and bulk sequencing data. | Front Immunol | 2023 | 36793711 | PubTator, text mining | PubMed |
| CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. | Cancer Cell | 2023 | 36787696 | PubTator, text mining | PubMed |
| Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. | Haematologica | 2023 | 36779592 | PubTator, text mining | PubMed |
| RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis. | Front Immunol | 2023 | 36776876 | PubTator, text mining | PubMed |
| CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm. | Int J Mol Sci | 2023 | 36769040 | PubTator, text mining | PubMed |
| Cell Immunotherapy against Melanoma: Clinical Trials Review. | Int J Mol Sci | 2023 | 36768737 | PubTator, text mining | PubMed |
| CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy. | Int J Mol Sci | 2023 | 36768665 | PubTator, text mining | PubMed |
| Molecular Mechanisms Underlying Neuroinflammation Elicited by Occupational Injuries and Toxicants. | Int J Mol Sci | 2023 | 36768596 | PubTator, text mining | PubMed |
| The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches. | Int J Mol Sci | 2023 | 36768342 | PubTator, text mining | PubMed |
| Immune-Activated B Cells Are Dominant in Prostate Cancer. | Cancers (Basel) | 2023 | 36765877 | PubTator, text mining | PubMed |
| The Immunology of DLBCL. | Cancers (Basel) | 2023 | 36765793 | PubTator, text mining | PubMed |
| Clinical and Immunologic Characteristics of Non-Hematologic Cancers in Patients with Inborn Errors of Immunity. | Cancers (Basel) | 2023 | 36765721 | PubTator, text mining | PubMed |
| Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. | Cancers (Basel) | 2023 | 36765668 | PubTator, text mining | PubMed |
| Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma. | Cancers (Basel) | 2023 | 36765544 | PubTator, text mining | PubMed |
| Cell-cell communications shape tumor microenvironment and predict clinical outcomes in clear cell renal carcinoma. | J Transl Med | 2023 | 36765369 | PubTator, text mining | PubMed |
| Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets. | Expert Opin Investig Drugs | 2023 | 36762937 | PubTator, text mining | PubMed |
| Circulating immune response proteins predict the outcome following disease progression of osimertinib treated epidermal growth factor receptor-positive non-small cell lung cancer patients. | Transl Lung Cancer Res | 2023 | 36762069 | PubTator, text mining | PubMed |
Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9-mediated gene-disruptions corroborate the MIR141/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired EMT-associated EGFR TKI-resistance in NSCLC cells. | Transl Lung Cancer Res | 2023 | 36762066 | PubTator, text mining | PubMed |
| EZH2-regulated immune risk score prognostic model predicts outcome of clear cell renal cell carcinoma. | Transl Androl Urol | 2023 | 36760869 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=45